Claims for Patent: 7,939,249

Summary for Patent: 7,939,249

Title:	Methods for nucleic acid isolation and kits using a microfluidic device and concentration step
Abstract:	The present invention provides methods and kits for isolating nucleic acid from a sample, preferably from a biological sample, using a microfluidic device and a concentration step.
Inventor(s):	Parthasarathy; Ranjani V. (Woodbury, MN), Ericson; Katya (Fairburn, GA), Bedingham; William (Woodbury, MN)
Assignee:	3M Innovative Properties Company (St. Paul, MN)
Application Number:	10/852,085
Patent Claims:	1. A method of separating nucleic acid from inhibitors in a sample, the method comprising: providing a microfluidic device comprising a valved process chamber, at least one additional chamber, and an axis of rotation; providing a sample comprising nucleic acid bound to beads and/or nucleic acid-containing material bound to beads, and inhibitors; placing the sample in the microfluidic device; positioning the sample in the valved process chamber; forming a concentrated region and a less concentrated region of the sample in the valved process chamber by rotating the microfluidic device about the axis of rotation, wherein the concentrated region of the sample comprises a majority of the beads with nucleic acid and/or nucleic acid-containing material bound thereto, and the less concentrated region comprises at least a portion of the inhibitors; and forming an opening in a valve septum of the valved process chamber at a desired location and rotating the microfluidic device to remove at least a portion of the less concentrated region of the sample and substantially separate the concentrated region from the less concentrated region of the sample thereby removing at least a portion of the inhibitors from the sample. 2. The method of claim 1, further comprising: diluting the separated concentrated region of the sample with water or buffer, further concentrating the diluted region to increase the concentration of beads with nucleic acid and/or nucleic acid-containing material bound thereto, separating the further concentrated region, and repeating this process of dilution followed by concentration and separation to reduce the inhibitor concentration to that which would not interfere with an amplification process; lysing nucleic acid-containing material, if present, with optional heating to release nucleic acid; adjusting the pH of the sample comprising nucleic acid; amplifying a particular nucleic acid in the sample; and detecting the particular nucleic acid. 3. A method of isolating nucleic acid from a sample, the method comprising: providing a microfluidic device comprising a valved process chamber, at least one additional chamber, and an axis of rotation; providing a sample comprising nucleic acid and inhibitors; placing the sample in the microfluidic device; positioning the sample in the valved process chamber; forming a concentrated region and a less concentrated region of the sample in the valved process chamber by rotating the microfluidic device about the axis of rotation, wherein the concentrated region of the sample comprises a majority of the nucleic acid-containing material, and the less concentrated region comprises at least a portion of the inhibitors; and forming an opening in a valve septum of the valved process chamber at a desired location and rotating the microfluidic device to remove at least a portion of the less concentrated region of the sample and substantially separate the concentrated region from the less concentrated region of the sample thereby removing at least a portion of the inhibitors from the sample. 4. The method of claim 3, wherein forming an opening in a valve septum includes forming a first opening in a valve septum, and further comprising forming a second opening in the valve septum of the valved process chamber at a desired location and rotating the microfluidic device to transfer the separated concentrated region of the sample to at least one additional chamber. 5. The method of claim 4, wherein forming a first opening in a valve septum of the valved process chamber at a desired location includes forming a first opening in a valve septum of the valved process chamber at a first location, and wherein forming a second opening in the valve septum in the valved process chamber includes forming a second opening in the valve septum of the valved process chamber at a second location, wherein the second location is located farther from the axis of rotation than the first location. 6. The method of claim 3, further comprising: diluting the separated concentrated region of the sample with water or buffer, further concentrating the diluted region to increase the concentration of nucleic acid material, separating the further concentrated region, and repeating this process of dilution followed by concentration and separation to reduce the inhibitor concentration to that which would not interfere with an amplification process; lysing nucleic acid-containing material, if present, with optional heating to release nucleic acid; adjusting the pH of the sample comprising nucleic acid; amplifying a particular nucleic acid in the sample; and detecting the particular nucleic acid. 7. The method of claim 6, wherein adjusting the pH comprises adjusting the pH to be within a range of 7.5 to 9. 8. The method of claim 3, wherein the sample comprises nucleic acid-containing material, cells containing inhibitors, and extracellular inhibitors. 9. The method of claim 3, wherein forming an opening in a valve septum of the valved process chamber comprises forming an opening in a valve septum to remove the upper 95 volume-% of the sample. 10. The method of claim 3, wherein the microfluidic device includes a solid phase material. 11. The method of claim 3, wherein the solid phase material comprises pathogen capture material and the sample comprises one or more pathogens. 12. The method of claim 11, wherein forming a concentrated region and a less concentrated region of the sample in the valved process chamber comprises contacting the sample with the pathogen capture material. 13. The method of claim 3, wherein forming a concentrated region and a less concentrated region of the sample in the valved process chamber comprises centrifuging the sample in the process chamber. 14. The method of claim 3, wherein: the sample comprises blood serum or plasma, and one or more pathogens; the method further comprises concentrating the one or more pathogens prior to placing the sample in the microfluidic device; and placing the sample in the microfluidic device comprises placing the concentrated one or more pathogens into the microfluidic device. 15. A method of isolating nucleic acid from a sample, the method comprising: providing a microfluidic device comprising a valved process chamber, at least one additional chamber, and an axis of rotation; providing a sample comprising nucleic acid-containing material, cells containing inhibitors, and optionally extracellular inhibitors; placing the sample in the microfluidic device; contacting the sample with a first lysing reagent under conditions effective to break cell membranes and release inhibitors and form a lysed sample comprising nucleic acid-containing material and inhibitors; positioning the lysed sample in the valved process chamber; forming a concentrated region and a less concentrated region of the lysed sample in the valved process chamber by rotating the microfluidic device, wherein the concentrated region of the lysed sample comprises a majority of the nucleic acid-containing material and the less concentrated region comprises at least a portion of the inhibitors; and forming an opening in a valve septum of the valved process chamber and rotating the microfluidic device about the axis of rotation to remove at least a portion of the less concentrated region of the sample and substantially separate the concentrated region from the less concentrated region of the lysed sample thereby removing at least a portion of the inhibitors from the lysed sample. 16. The method of claim 15, further comprising: diluting the separated concentrated region of the lysed sample with water or buffer, further concentrating the diluted region to increase the concentration of nucleic acid material, separating the further concentrated region, and repeating this process of dilution followed by concentration and separation to reduce the inhibitor concentration to that which would not interfere with an amplification method; further lysing the nucleic acid-containing material to release nucleic acid; and adjusting the pH of the sample comprising released nucleic acid. 17. The method of claim 16, wherein further lysing the nucleic acid-containing material to release nucleic acid comprises subjecting the nucleic acid-containing material to a heating/cooling process. 18. The method of claim 16, wherein further lysing the nucleic acid-containing material to release nucleic acid comprises subjecting the nucleic acid-containing material to a strong base with optional heating, wherein the strong base has a pH that is effective for an alkaline lysis. 19. The method of claim 16, wherein adjusting the pH of the sample comprising the released nucleic acid includes adjusting the pH to be within a range of 7.5 to 9. 20. The method of claim 16, further comprising transferring the sample comprising released nucleic acid to an amplification reaction chamber. 21. The method of claim 20, further comprising amplifying the released nucleic acid. 22. The method of claim 15, further comprising: diluting the separated concentrated region of the lysed sample with water or buffer, further concentrating the diluted region to increase the concentration of nucleic acid material, separating the further concentrated region, and repeating this process of dilution followed by concentration and separation to reduce the inhibitor concentration to that which would not interfere with an amplification method; further lysing the nucleic acid-containing material with a strong base and heat to release nucleic acid, wherein the strong base has a pH that is effective for an alkaline lysis procedure; and adjusting the pH of the sample comprising released nucleic acid. 23. The method of claim 15, further comprising diluting the separated concentrated region of the lysed sample with water to reduce the concentration of heme to less than 2 micromolar. 24. The method of claim 23, wherein the water is RNAse-free sterile water. 25. The method of claim 15, wherein forming an opening in a valve septum of the valved process chamber comprises forming an opening in a valve septum to remove the upper 95 volume-% of the sample. 26. The method of claim 15, wherein the nucleic acid-containing material comprises nuclei. 27. The method of claim 15, wherein placing the sample in the microfluidic device occurs prior to contacting the sample with a first lysing reagent. 28. The method of claim 15, wherein the microfluidic device further comprises a loading chamber, wherein the loading chamber comprises the first lysing reagent, wherein placing the sample in the microfluidic device includes placing the sample in the loading chamber, and wherein contacting the sample with a first lysing reagent occurs upon placing the biological sample in the loading chamber. 29. The method of claim 15, wherein placing the sample in the microfluidic device occurs after contacting the sample with a first lysing reagent. 30. The method of claim 15, wherein forming a concentrated region and a less concentrated region of the sample in the valved process chamber comprises centrifuging the sample in the process chamber. 31. The method of claim 15, wherein the first lysing reagent is a nonionic surfactant. 32. The method of claim 15, wherein the sample comprises nucleic acid-containing material, cells containing inhibitors, and extracellular inhibitors. 33. The method of claim 1, wherein forming an opening in a valve septum includes forming a first opening in a valve septum, and further comprising forming a second opening in the valve septum of the valved process chamber at a desired location and rotating the microfluidic device to transfer the separated concentrated region of the sample to at least one additional chamber. 34. The method of claim 1, wherein forming a first opening in a valve septum of the valved process chamber at a desired location includes forming a first opening in a valve septum of the valved process chamber at a first location, and wherein forming a second opening in the valve septum in the valved process chamber includes forming a second opening in the valve septum of the valved process chamber at a second location, wherein the second location is located farther from the axis of rotation than the first location.

Details for Patent 7,939,249

Applicant	Tradename	Biologic Ingredient	Dosage Form	BLA	Approval Date	Patent No.	Expiredate
Merck Sharp & Dohme Corp.	ZOSTAVAX	zoster vaccine live	For Injection	125123	05/25/2006		2023-12-24